Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A. Yu, Jonathan W. Riess, Julie Maidment et al.|Clinical Lung Cancer|2021Cited by 73
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinibHelena A. Yu, Xiuning Le, Helen Ambrose et al.|Annals of Oncology|2021Cited by 47
1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARDX. Le, Sarah B. Goldberg, L. Hendriks et al.|Journal of Thoracic Oncology|2025Cited by 22
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor–Mutated Advanced Non–Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W. Riess, Helena A. Yu, Adrianus J. de Langen et al.|JCO Precision Oncology|2025Cited by 10
1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinibJ. De Langen, Helena A. Yu, B.C. Cho et al.|Annals of Oncology|2022Cited by 7